Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Glynne Jones R, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, Van de Velde C, Schmoll HJ, Sobrero A, Tabernero J
Ann Oncol. 2010 21 Suppl 6: vi1-10

PMID: 20534623 · DOI:10.1093/annonc/mdq273

The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy for mCRC treatment. The meeting was conducted during the 11th ESMO/World Gastrointestinal Cancer Congress (WGICC) in Barcelona in June 2009. The manuscript describes the outcome of an expert discussion leading to an expert recommendation. The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC.

MeSH Terms (15)

Antineoplastic Agents Biomarkers Carcinoembryonic Antigen Colorectal Neoplasms ErbB Receptors Humans Microsatellite Instability Mutation Neoplasm Metastasis Prognosis Proto-Oncogene Proteins Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins p21(ras) ras Proteins Spain

Connections (1)

This publication is referenced by other Labnodes entities: